Immunotherapy has moved to the center stage of cancer treatment with the recent success of
trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a …

Background Several accomplishments have been achieved in triple-negative breast cancer
(TNBC) research over the last year. The phase III IMpassion130 trial comparing …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent
developments in cancer immunotherapy have had significant clinical impact, only a subset …

Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1)
and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of
targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors …

Triple-negative breast cancer (TNBC) is a special subtype of breast cancer, accounting for
10–20% of breast cancers with high intrinsic heterogeneity. Its unique immune …

Background The T-cell inhibitory molecule PD-L1 (B7-H1, CD274) is expressed on tumor
cells of a subset of breast cancer patients. However, the mechanism that regulates PD-L1 …

Breast cancer is the most prevalent cancer in women worldwide. Triple-negative breast
cancer (TNBC) is characterized by the lack of expression of estrogen receptor, progesterone …